Zolgensma

Zolgensma (onasemnogene abeparvovec) is a gene therapy designed to treat spinal muscular atrophy (SMA), a rare genetic disorder that causes progressive muscle weakness and loss of movement. SMA occurs because of a missing or faulty SMN1 gene, which is responsible for producing survival motor neuron (SMN) protein. This protein is essential for the function and survival of motor neurons that control muscle movement.
Zolgensma works by delivering a healthy copy of the SMN1 gene into the body using a specially engineered viral vector. Once inside the cells, this new gene enables the production of functional SMN protein, helping protect motor neurons and supporting normal muscle function. Unlike long-term treatment approaches that require repeated dosing, Zolgensma is given as a single intravenous infusion, making it a one-time gene replacement therapy.
This therapy is primarily used for infants and very young children diagnosed with SMA, especially those with the most severe forms of the condition. Clinical studies have shown that early treatment can significantly improve survival, motor development, and physical milestones such as sitting, crawling, and breathing independently. Children treated early often achieve abilities that were previously very rare for SMA patients.
Zolgensma represents a major breakthrough in genetic medicine, as it addresses the root cause of SMA rather than only managing symptoms. It has also helped transform how genetic diseases are approached, demonstrating the potential of gene therapy to provide long-lasting benefits through a single treatment. As research advances, therapies like Zolgensma continue to shape the future of care for inherited disorders by offering targeted, science-driven solutions